Skip to main content
Erschienen in: Endocrine 3/2014

01.04.2014 | Original Article

Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications

verfasst von: Isabella Merante Boschin, Francesca Torresan, Antonio Toniato, Mariangela Zane, Eric Casal Ide, Gianmaria Pennelli, Lucia Rampin, Patrick M. Colletti, Domenico Rubello, Maria Rosa Pelizzo

Erschienen in: Endocrine | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

To investigate whether further, diagnostic procedures should be recommended in patients with slight increase of preoperative serum basal calcitonin (bCT) levels in whom surgical treatment can be recommendable. Fourteen consecutive patients with nodular thyroid disease underwent thyroidectomy in our center for suspected medullary thyroid microcarcinoma (MTC) because their serum bCT levels were slightly higher than the upper limit of normal range. Serum bCT was measured by radioimmunoassay, normality range = 0–20 ng/L. Surgical specimens were examined by the same pathologist using histologic and immunohistochemistry techniques. An extensive search for parafollicular C-cell hyperplasia (CCH) and/or microscopic MTC foci was performed. At preoperative ultrasound, a single thyroid nodule was depicted in three patients while a multinodular goiter in 11. The bCT values ranged between 24.4 and 94.6 ng/L, median 42.2 ng/L while the pentagastrin-stimulated CT (sCT) values by pentagastrin test ranged between 61.5 and 1,262 ng/L, median 245.0 ng/L. Total thyroidectomy was performed in 13 patients, and lobectomy in the other one; central node dissection was also performed in eight cases. At histology, MTC was diagnosed in nine patients (64.3 %), showing a median maximum diameter of 6.1 mm (range, 1.5–17 mm); CCH was diagnosed in the other five patients (35.7 %). The pentagastrin stimulation test was obtained in all patients. It is worth noting that a very high increase of sCT >100 ng/mL was observed in 5/9 patients with MTC and in 2/4 patients with HCC, therefore suggesting the absence of a relationship between the entity of response to pentagastrin test with a specific pathology (MTC vs. HCC). In six patients, the MTC was the nodule on which preoperative FNAC had been performed, while in other three patients preoperative FNAC had been performed on a different nodule from the MTC. Based on our experience, in case of the pentagastrin stimulation test with sCT <100 ng/L and a single nodule, the CT assay on FNAC may be useful, subsequently lobectomy with definitive histological diagnosis is recommended. In case of the Pg test with sCT <100 ng/L and bilateral goiter, total thyroidectomy with histological diagnosis is recommended. In this way, as for the surgical procedure, total thyroidectomy is recommended in cases of bilateral goiter, while lobectomy can be offered for cases with single nodes with serum dosage of bCT in the strict follow up. In case of the pentagastrin stimulating test with sCT <100 ng/L and bilateral goiter, total thyroidectomy with histological diagnosis is recommended.
Literatur
1.
Zurück zum Zitat G. Karanikas, A. Moameni, C. Poetzi, G. Zetting, K. Kaserer, C. Bieglmayer et al., Frequency and relevance of elevated calcitonin levels in patients with nonneoplastic thyroid disease and in healthy subjects. J. Clin. Endocrinol. Metab. 89, 515–519 (2004)PubMedCrossRef G. Karanikas, A. Moameni, C. Poetzi, G. Zetting, K. Kaserer, C. Bieglmayer et al., Frequency and relevance of elevated calcitonin levels in patients with nonneoplastic thyroid disease and in healthy subjects. J. Clin. Endocrinol. Metab. 89, 515–519 (2004)PubMedCrossRef
2.
Zurück zum Zitat R. Seth, P. Motte, A. Kehely, S.J. Wimalawansa, C.H. Self, D. Bellet et al., Sensitive and specific two site enzyme immunoassay for human calcitonin using monoclonal antibodies. J. Endocrinol. 119, 351–357 (1998)CrossRef R. Seth, P. Motte, A. Kehely, S.J. Wimalawansa, C.H. Self, D. Bellet et al., Sensitive and specific two site enzyme immunoassay for human calcitonin using monoclonal antibodies. J. Endocrinol. 119, 351–357 (1998)CrossRef
3.
Zurück zum Zitat N. Barbot, C. Calmettes, I. Schuffenecker, J.P. Saint Andre, B. Franc, V. Rohmer et al., Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 114–120 (1994)PubMed N. Barbot, C. Calmettes, I. Schuffenecker, J.P. Saint Andre, B. Franc, V. Rohmer et al., Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 114–120 (1994)PubMed
4.
Zurück zum Zitat J.F. Henry, A. Denizot, M. Puccini, L. Gramatica, A. Kvachenyuk, B. Conte Devolx et al., Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J. Surg. 22, 727–752 (1998)CrossRef J.F. Henry, A. Denizot, M. Puccini, L. Gramatica, A. Kvachenyuk, B. Conte Devolx et al., Latent subclinical medullary thyroid carcinoma: diagnosis and treatment. World J. Surg. 22, 727–752 (1998)CrossRef
5.
Zurück zum Zitat F. Pacini, M. Fontanelli, L. Fugazzola, R. Elisei, C. Romei, G. Di Cosia et al., Routine measurement of serum calcitonin in nodular thyroid disease allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 826 (1994)PubMed F. Pacini, M. Fontanelli, L. Fugazzola, R. Elisei, C. Romei, G. Di Cosia et al., Routine measurement of serum calcitonin in nodular thyroid disease allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 78, 826 (1994)PubMed
6.
Zurück zum Zitat M. Rieu, M.C. Lame, A. Richard, B. Lissak, B. Sambort, P. Vuong Ngoc et al., Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf.) 42, 453 (1995)CrossRef M. Rieu, M.C. Lame, A. Richard, B. Lissak, B. Sambort, P. Vuong Ngoc et al., Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf.) 42, 453 (1995)CrossRef
7.
Zurück zum Zitat L.M. Thienpont, K. Van Uyfanghe, S. Van Houce, IFCC working group for standardization of thyroid function tests (WG_STFT): standardization activitiesb in the field of thyroid function tests: a status repoprt. Clin. Chem. Lab. Med. 48, 1577–1583 (2010)PubMedCrossRef L.M. Thienpont, K. Van Uyfanghe, S. Van Houce, IFCC working group for standardization of thyroid function tests (WG_STFT): standardization activitiesb in the field of thyroid function tests: a status repoprt. Clin. Chem. Lab. Med. 48, 1577–1583 (2010)PubMedCrossRef
8.
Zurück zum Zitat P. Doyle, C. Duren, K. Nerlich, F.A. Verburg, I. Grelle, H. Jahn et al., Potency and tolerance of calcitonin stimulation with high dose calcium versus pentagastrin in normal adults. J. Clin. Endocrinol. Metab. 94, 2970–2974 (2009)PubMedCrossRef P. Doyle, C. Duren, K. Nerlich, F.A. Verburg, I. Grelle, H. Jahn et al., Potency and tolerance of calcitonin stimulation with high dose calcium versus pentagastrin in normal adults. J. Clin. Endocrinol. Metab. 94, 2970–2974 (2009)PubMedCrossRef
9.
Zurück zum Zitat T. Rink, P.N. Truong, H.J. Schorth, J. Diener, M. Zinny, J. Diener et al., Calculation and validation of a plasma calcitonin limitfor early detection of medullary thyroid carcinoma in nodular disease. Thyroid 19, 327–332 (2009)PubMedCrossRef T. Rink, P.N. Truong, H.J. Schorth, J. Diener, M. Zinny, J. Diener et al., Calculation and validation of a plasma calcitonin limitfor early detection of medullary thyroid carcinoma in nodular disease. Thyroid 19, 327–332 (2009)PubMedCrossRef
10.
Zurück zum Zitat M. d’Herbomez, P. Caron, C. Bauster, C. Do Cao, J.L. Schlienger, R. Sapin et al., Reference range of serum calcitonin levels in humans: influence of calcitonin assay, sex, age and cigarette smoking. Eur. J. Endocrinol. 157, 749–755 (2007)PubMedCrossRef M. d’Herbomez, P. Caron, C. Bauster, C. Do Cao, J.L. Schlienger, R. Sapin et al., Reference range of serum calcitonin levels in humans: influence of calcitonin assay, sex, age and cigarette smoking. Eur. J. Endocrinol. 157, 749–755 (2007)PubMedCrossRef
11.
Zurück zum Zitat C. Colombo, U. Verga, C. Mian, S. Ferrero, M. Perrino, L. Vicentini et al., Comparison of calcium and pentagastrin for the diagnosis and follow up of medullary thyroid cancer. J. Clin. Endocrinol. Metab. 97, 905–913 (2012)PubMedCrossRef C. Colombo, U. Verga, C. Mian, S. Ferrero, M. Perrino, L. Vicentini et al., Comparison of calcium and pentagastrin for the diagnosis and follow up of medullary thyroid cancer. J. Clin. Endocrinol. Metab. 97, 905–913 (2012)PubMedCrossRef
12.
Zurück zum Zitat R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, H. Gharib, J.F. Moley et al., Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565–612 (2009)PubMedCrossRef R.T. Kloos, C. Eng, D.B. Evans, G.L. Francis, H. Gharib, J.F. Moley et al., Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565–612 (2009)PubMedCrossRef
13.
Zurück zum Zitat G. Pina, S. Dubois, A. Murat, N. Berger, P. Niccoli, J.L. Peix et al., Is basal ultrasensitive of calcitonin capable of substituting for the pentagastrin-stimulation test? Clin Endocrinol (Oxf) 78, 358–364 (2013)CrossRef G. Pina, S. Dubois, A. Murat, N. Berger, P. Niccoli, J.L. Peix et al., Is basal ultrasensitive of calcitonin capable of substituting for the pentagastrin-stimulation test? Clin Endocrinol (Oxf) 78, 358–364 (2013)CrossRef
14.
Zurück zum Zitat E.M. Santos, J.F. Paula, P.M. Motta, M.B. Heinemann, R.C. Leite, J.P. Haddad et al., Comparison of three methods of DNA extraction from peripheral blood mononuclear cells and lung fragments of equines. Genet. Mol. Res. 9, 1591–1598 (2010)PubMedCrossRef E.M. Santos, J.F. Paula, P.M. Motta, M.B. Heinemann, R.C. Leite, J.P. Haddad et al., Comparison of three methods of DNA extraction from peripheral blood mononuclear cells and lung fragments of equines. Genet. Mol. Res. 9, 1591–1598 (2010)PubMedCrossRef
15.
Zurück zum Zitat M.R. Pelizzo, I.M. Boschin, S. Barollo, G. Pennelli, A. Toniato, L. Zambonin et al., BRAF analisis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin. Chem. Lab. Med. 49, 325–329 (2011)PubMedCrossRef M.R. Pelizzo, I.M. Boschin, S. Barollo, G. Pennelli, A. Toniato, L. Zambonin et al., BRAF analisis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. Clin. Chem. Lab. Med. 49, 325–329 (2011)PubMedCrossRef
16.
Zurück zum Zitat U. Verga, S. Ferrero, L. Vincentini, T. Brambilla, V. Cirello, M. Muzza et al., Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr. Relat. Cancer 14, 393–403 (2007)PubMedCrossRef U. Verga, S. Ferrero, L. Vincentini, T. Brambilla, V. Cirello, M. Muzza et al., Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia? Endocr. Relat. Cancer 14, 393–403 (2007)PubMedCrossRef
17.
Zurück zum Zitat C. Scheuba, K. Kaserer, A. Moritz, R. Drosten, H. Vierhapper, C. Bieglmayer et al., Sporadic hypercalcitoninemia: clinical and therapeutic consequences. Endocr. Relat. Cancer 16, 243–253 (2009)PubMedCrossRef C. Scheuba, K. Kaserer, A. Moritz, R. Drosten, H. Vierhapper, C. Bieglmayer et al., Sporadic hypercalcitoninemia: clinical and therapeutic consequences. Endocr. Relat. Cancer 16, 243–253 (2009)PubMedCrossRef
18.
Zurück zum Zitat R. Elisei, V. Bottici, F. Lucchetti, G. Di Coscio, C. Romei, L. Grasso et al., Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J. Clin. Endocrinol. Metab. 89, 163–168 (2004)PubMedCrossRef R. Elisei, V. Bottici, F. Lucchetti, G. Di Coscio, C. Romei, L. Grasso et al., Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J. Clin. Endocrinol. Metab. 89, 163–168 (2004)PubMedCrossRef
19.
Zurück zum Zitat Z. Baloch, P. Carayon, B. Conte-Devolx, L.M. Demers, U. Feldt-Rasmussen, J.F. Henry et al., Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13, 3–126 (2003)PubMedCrossRef Z. Baloch, P. Carayon, B. Conte-Devolx, L.M. Demers, U. Feldt-Rasmussen, J.F. Henry et al., Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13, 3–126 (2003)PubMedCrossRef
Metadaten
Titel
Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications
verfasst von
Isabella Merante Boschin
Francesca Torresan
Antonio Toniato
Mariangela Zane
Eric Casal Ide
Gianmaria Pennelli
Lucia Rampin
Patrick M. Colletti
Domenico Rubello
Maria Rosa Pelizzo
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0019-7

Weitere Artikel der Ausgabe 3/2014

Endocrine 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.